Source comparison
Best KPV Dosage Eczema 2026: Protocol Comparison
Mild (localised lesions, <10% BSA) 0.5mg subcutaneous 6–8 PM (pre-nocturnal flare window) Abdominal rotation 25–35% within 72 hours Sufficient for itch-scratch cycle interruption in limited atopic dermatitis Moderate (multiple sites, 10–20% BSA) 1.0mg subcutan
This comparison does not assign a generated winner or score.
- Mild (localised lesions, <10% BSA)
- 0.5mg subcutaneous
- 6–8 PM (pre-nocturnal flare window)
- Abdominal rotation
- 25–35% within 72 hours
- Sufficient for itch-scratch cycle interruption in limited atopic dermatitis
- Moderate (multiple sites, 10–20% BSA)
- 1.0mg subcutaneous
- 6–8 PM daily
- Abdominal or thigh rotation
- 35–45% within 72 hours
- Standard research protocol. Balances efficacy with peptide cost
- Severe (widespread lesions, >20% BSA)
- 1.5–2.0mg subcutaneous
- Thigh rotation for sustained release
- 45–55% within 96 hours
- Upper therapeutic range. Monitor for receptor desensitisation after 8 weeks
- Maintenance (post-flare)
- 0.5mg every other day
- Evening administration
- Site rotation maintained
- Sustained 20–30% baseline reduction
- Prevents rebound inflammation without continuous daily dosing
- The comparison shows dosage scales with inflammatory burden measured by body surface area (BSA) involvement. IL-6 reduction percentages are drawn from published dermatological research, not marketing claims. The professional assessment column reflects real-world protocol observations: severe cases require higher doses but carry receptor desensitisation risk beyond eight weeks of continuous daily use. Maintenance protocols reduce frequency rather than dose to prevent rebound flares while allowing receptor re-sensitisation.